AUTHOR=Huang Lei , Liu Mei-Qing , Wan Chang-Qing , Cheng Ning-Ning , Su Yan-Bin , Zheng Yan-Peng , Peng Xiang-Lei , Yu Jie-Mei , Fu Yuan-Hui , He Jin-Sheng 

TITLE=The protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing human respiratory syncytial virus prefusion fusion glycoprotein in BALB/c mice

JOURNAL=Frontiers in Microbiology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1041338

DOI=10.3389/fmicb.2022.1041338

ISSN=1664-302X

ABSTRACT=<p>Human respiratory syncytial virus (RSV) is a ubiquitous pediatric pathogen causing serious lower respiratory tract disease worldwide. No licensed vaccine is currently available. In this work, the coding gene for mDS-Dav1, the full-length and prefusion conformation RSV fusion glycoprotein (F), was designed by introducing the stabilized prefusion F (preF) mutations from DS-Cav1 into the encoding gene of wild-type RSV (<italic>wt</italic>RSV) F protein. The recombinant adenovirus encoding mDS-Cav1, rChAd63-mDS-Cav1, was constructed based on serotype 63 chimpanzee adenovirus vector and characterized <italic>in vitro</italic>. After immunizing mice <italic>via</italic> intranasal route, the rChAd63-mDS-Cav1 induced enhanced neutralizing antibody and F-specific CD8<sup>+</sup> T cell responses as well as good immune protection against RSV challenge with the absence of enhanced RSV disease (ERD) in BALB/c mice. The results indicate that rChAd63-mDS-Cav1 is a promising mucosal vaccine candidate against RSV infection and warrants further development.</p>